NCT06583278Not yet recruiting
The Efficacy of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease：A Randomized, Double-blind, Multicenter, Placebo-controlled Trial
Source: ClinicalTrials.gov · Last updated 4 Sept 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 312 (estimated)
- First submitted
- 1 Sept 2024
- Start date
- 1 Nov 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Anhui Medical University
- Diseases
- Parkinson disease
- NCT number
- NCT06583278
What you commit to
- Study type: Interventional
- Planned participants: 312
- From 1 Nov 2024 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;
- Participants in any clinical trial within the previous 6 month;
Other illness
- Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);
- There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.
- The person or first-degree relatives have a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures;
- Diagnosed with a neuropsychiatric disorder other than PD
- Have a history of drug abuse or drug use;
- Other conditions deemed unsuitable for inclusion by the investigator.
Other
- Head MRI/CT ruled out focal brain injury or severe leukoencephalopathy (Fazekas grade 3);
- Pregnant/lactating women or subjects (including men) who have a birth plan within 6 months;
Who the study is looking for
- Age ≥40 years old
- Meet Movement Disorder Society standards;
- Have no history of drug adjustment within 4 weeks before and during treatment;
- The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4
- MMSE ≥24，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.